PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10458245-11	1999	CONCLUSION: CD56+ acute promyelocytic leukemia is infrequent, seems to occur more frequently with the S-isoform subtype, and may be associated with a lower CR rate and inferior overall survival.	Chromium	156-158	neural cell adhesion molecule 1	Homo sapiens	12-16	
22939316-11	2013	CD56 remained an independent predictor for lower CR rate (P = .021) and shorter event-free survival (P = .002).	Chromium	49-51	neural cell adhesion molecule 1	Homo sapiens	0-4	
9269784-10	1997	Although post-CR therapy did not differ, CR duration was significantly shorter in cases with CD56 expression compared with those without (median, 8.7 months v not reached; P = .01), as was survival (median, 16.5 months v not reached; P = .008).	Chromium	41-43	neural cell adhesion molecule 1	Homo sapiens	93-97	
9269784-11	1997	We conclude that CD56 expression in AML with t(8;21) is associated with significantly shorter CR duration and survival.	Chromium	94-96	neural cell adhesion molecule 1	Homo sapiens	17-21	
27531762-7	2016	The CR after the first course chemotherapy and cumulative CR in CD56(+) AML patients were lower than those in the control group (20.0% vs 58.1%, P=0.0099; 73.3% vs 87.5%, P=0.04).	Chromium	4-6	neural cell adhesion molecule 1	Homo sapiens	64-68	
23815905-9	2013	The CR rate in CD56(+) group accounted for 60.0%, and had no significant difference in comparison with that in CD56(-) group.	Chromium	4-6	neural cell adhesion molecule 1	Homo sapiens	15-19	
14559689-9	2003	The expressions of CD56+, CD34+, lymphoid antigen in adult AML patients, who have lower CR rate, often signify poor prognosis.	Chromium	88-90	neural cell adhesion molecule 1	Homo sapiens	19-23	
19568712-12	2009	The expression of CD56 was significantly associated with a lower CR rate (P<0.05), but did not affect DFS and OS.	Chromium	65-67	neural cell adhesion molecule 1	Homo sapiens	18-22	
12414342-9	2002	CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002).	Chromium	54-56	neural cell adhesion molecule 1	Homo sapiens	0-4	
12414342-9	2002	CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002).	Chromium	54-56	neural cell adhesion molecule 1	Homo sapiens	79-83	
12414342-9	2002	CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002).	Chromium	54-56	neural cell adhesion molecule 1	Homo sapiens	79-83	
12414342-9	2002	CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002).	Chromium	54-56	neural cell adhesion molecule 1	Homo sapiens	79-83	
12414342-9	2002	CD56+ and PGP+ on AML cells significantly reduced the CR rate (83% in the PGP-/CD56- group vs 60% in the PGP-/CD56+ group, 46% in the PGP+/CD56- group and 58% in the PGP+/CD56+ group, p = 0.002).	Chromium	54-56	neural cell adhesion molecule 1	Homo sapiens	79-83